ENLV logo

Enlivex Therapeutics (ENLV) Company Overview

Profile

Full Name:

Enlivex Therapeutics Ltd.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

July 31, 2014

Indexes:

Not included

Description:

Enlivex Therapeutics (ENLV) is a biotechnology company focused on developing innovative therapies to treat severe autoimmune and inflammatory diseases. Their main product, Allocetra, aims to restore immune balance and improve patient outcomes in conditions like sepsis and organ transplant rejection.

Events Calendar

Earnings

Next earnings date:

Mar 10, 2025

Recent quarterly earnings:

Aug 30, 2024

Recent annual earnings:

Apr 30, 2020
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Mar 6, 2019

Analyst ratings

Recent major analysts updates

Mar 3, 25 D. Boral Capital
Buy
Feb 7, 25 D. Boral Capital
Buy
Dec 11, 24 D. Boral Capital
Buy
Dec 3, 24 D. Boral Capital
Buy
Nov 14, 24 D. Boral Capital
Buy
Sep 27, 24 HC Wainwright & Co.
Buy
Sep 26, 24 EF Hutton
Buy
Sep 24, 24 EF Hutton
Buy
Sep 9, 24 HC Wainwright & Co.
Buy
Aug 27, 24 EF Hutton
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Enlivex Therapeutics?
  • Does Enlivex Therapeutics pay dividends?
  • What sector is Enlivex Therapeutics in?
  • What industry is Enlivex Therapeutics in?
  • What country is Enlivex Therapeutics based in?
  • When did Enlivex Therapeutics go public?
  • Is Enlivex Therapeutics in the S&P 500?
  • Is Enlivex Therapeutics in the NASDAQ 100?
  • Is Enlivex Therapeutics in the Dow Jones?
  • When was Enlivex Therapeutics's last earnings report?
  • When does Enlivex Therapeutics report earnings?
  • Should I buy Enlivex Therapeutics stock now?

What is the ticker symbol for Enlivex Therapeutics?

The ticker symbol for Enlivex Therapeutics is NASDAQ:ENLV

Does Enlivex Therapeutics pay dividends?

No, Enlivex Therapeutics does not pay dividends

What sector is Enlivex Therapeutics in?

Enlivex Therapeutics is in the Healthcare sector

What industry is Enlivex Therapeutics in?

Enlivex Therapeutics is in the Biotechnology industry

What country is Enlivex Therapeutics based in?

Enlivex Therapeutics is headquartered in Israel

When did Enlivex Therapeutics go public?

Enlivex Therapeutics's initial public offering (IPO) was on July 31, 2014

Is Enlivex Therapeutics in the S&P 500?

No, Enlivex Therapeutics is not included in the S&P 500 index

Is Enlivex Therapeutics in the NASDAQ 100?

No, Enlivex Therapeutics is not included in the NASDAQ 100 index

Is Enlivex Therapeutics in the Dow Jones?

No, Enlivex Therapeutics is not included in the Dow Jones index

When was Enlivex Therapeutics's last earnings report?

Enlivex Therapeutics's most recent earnings report was on Aug 30, 2024

When does Enlivex Therapeutics report earnings?

The next expected earnings date for Enlivex Therapeutics is Mar 10, 2025

Should I buy Enlivex Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions